Condition: Pulmonary Fibrosis, Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis · Sponsor: Vejle Hospital
This study will investigate whether the senicapoc drug can prevent the scarring from worsening in interstitial lung disease. Researchers will compare Senicapoc to a placebo (a look-alike substance that contains no drug) to see if Senicapoc works to prevent lung function worsening. Participants will be asked to take 3 tablets a day for 26 weeks. Within this period, doctors will follow the participants, ask for experience of adverse events, check lung function and organ status, and participants will need to fill out quality-of-life questionnaires. A total of 5 visits are required, at initiation, after4, 13, 26 and 52 weeks. The final visit will occur 52 weeks after initiation and consist of a normal visit in the outpatient clinic where the doctor asks for relevant information regarding the period after end of administration of the study drug.
This description comes directly from the study's public registry record.
Line Kølner-Augustson, MD. · +45 28773005 · line.augustson@rsyd.dk
Always discuss trial participation with your own doctor first.
| Aarhus University Hospital | Aarhus N, Denmark | Recruiting |
| Kardiologisk Forskningsenhed 2161, Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Tartu University Hospital, | Tartu, Estonia | Recruiting |
| Division of Respiratory Sciences, Glenfield Hospital | Leicester, United Kingdom | Not Yet Recruiting |
| University of East Anglia | Norwich, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06714123